

To: CN=Joan Shen/OU=AM/O=LLY@Lilly
CC: CN=Patrizia Cavazzoni/OU=AM/O=LLY@Lilly; CN=Cherri Miner/OU=AM/O=LLY@Lilly
Date: 11/17/2003 01:33:32 PM
From: CN=Ludmila Kryzhanovskaya/OU=AM/O=LLY
Subject: HGKR (glucose and cholesterol)

Joan,

This is a response to your questions on Friday regarding the HGKR study collection of safety information and future SAP. In our new Zyprexa protocol template we are requiring all olanzapine clinical trials to collect fasting glucose and fasting lipids, including triglycerides. I have discussed these issues with Patrizia and she confirmed that the FDA requested to start doing it systematically in our studies more than one year ago.

Please let me know if you have any questions.

Ludmila
12802

Page: 1 of 1